Capricor's cell therapy shows improved heart and muscle function in Duchenne muscular dystrophy patients

statnews.com

Capricor Therapeutics announced its cell therapy significantly improved heart and muscle function in Duchenne muscular dystrophy patients. This positive outcome met the primary goals of a Phase 3 study, potentially reversing the FDA's prior rejection of the treatment. The company believes these new, robust results will persuade the FDA to approve its therapy, deramiocel.


With a significance score of 4.1, this news ranks in the top 4.5% of today's 29316 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Capricor's cell therapy shows improved heart and muscle function in Duchenne muscular dystrophy patients | News Minimalist